Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Naunyn Schmiedebergs Arch Pharmacol
2003 Nov 01;3685:404-14. doi: 10.1007/s00210-003-0805-5.
Show Gene links
Show Anatomy links
Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
Scholz EP
,
Zitron E
,
Kiesecker C
,
Lueck S
,
Kathöfer S
,
Thomas D
,
Weretka S
,
Peth S
,
Kreye VA
,
Schoels W
,
Katus HA
,
Kiehn J
,
Karle CA
.
???displayArticle.abstract???
Budipine is a non-dopaminergic antiparkinsonian drug causing acquired forms of Long QT syndrome (aLQTS). As a consequence, the manufacturer has restricted the use of budipine in patients who exhibit additional risk factors for the development of "Torsades-de-Pointes" tachycardias (TdP). The molecular basis of this serious side effect has not been elucidated yet. Human ether-a-go-go related gene (HERG) channel block being the main cause of drug induced QT prolongation, we investigated the effect of budipine on the rapid component of the delayed-rectifier potassium current (I(K(r))) in guinea pig cardiomyocytes and on HERG potassium channels heterologously expressed in Xenopus oocytes. In guinea pig cardiomyocytes, budipine (10 microM) inhibited I(K(r)) by 86% but was without any effect on calcium currents. In Xenopus oocytes, HERG potassium channels were blocked by budipine with an IC(50) of 10.2 microM. Onset of block was fast and block was only slowly and incompletely reversible upon washout. Budipine blocked HERG channels in the open and inactivated state, but not in the closed states. The half-maximal activation voltage was slightly shifted towards more negative potentials. Steady-state inactivation of HERG was also influenced by budipine. Budipine block was neither voltage- nor frequency-dependent. In HERG channel mutants Y652A and F656A, drug affinity was reduced dramatically. Therefore, these two aromatic residues in the channel pore are likely to form a main part of the binding site for budipine. In summary, this is the first study that provides a molecular basis for the budipine-associated aLQTS observed in clinical practice. Furthermore, these findings underline the importance of the aromatic residues Y652 and F656 in the binding of lipophilic drugs to HERG channels.
Bethke,
Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.
2001, Pubmed
Bethke,
Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.
2001,
Pubmed
Bleich,
KVLQT channels are inhibited by the K+ channel blocker 293B.
1997,
Pubmed
,
Xenbase
Curran,
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
1995,
Pubmed
Fabiato,
Calculator programs for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells.
1979,
Pubmed
January,
Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2.
2000,
Pubmed
Karle,
The antiarrhythmic drug BRL-32872.
2002,
Pubmed
Karle,
Rapid component I(Kr) of the guinea-pig cardiac delayed rectifier K(+) current is inhibited by beta(1)-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways.
2002,
Pubmed
Kiehn,
Differential effects of the new class III agent dofetilide on potassium currents in guinea pig cardiomyocytes.
1994,
Pubmed
Kiehn,
Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.
1996,
Pubmed
,
Xenbase
Kiehn,
Pathways of HERG inactivation.
1999,
Pubmed
,
Xenbase
Madeja,
Follicular tissues reduce drug effects on ion channels in oocytes of Xenopus laevis.
1997,
Pubmed
,
Xenbase
Menge,
[Summarizing description of the pharmacology of budipine, a new 4,4-diphenylpiperidine derivative used in Parkinson therapy (author's transl)].
1982,
Pubmed
Milnes,
Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
2003,
Pubmed
Mitcheson,
Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.
2000,
Pubmed
,
Xenbase
Mitcheson,
Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine.
2003,
Pubmed
Mitcheson,
A structural basis for drug-induced long QT syndrome.
2000,
Pubmed
,
Xenbase
Priori,
Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes.
2002,
Pubmed
Redfern,
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
2003,
Pubmed
Roden,
Cardiac ion channels.
2002,
Pubmed
Schaefer,
[Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines].
1984,
Pubmed
Spector,
Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
1996,
Pubmed
,
Xenbase
Witchel,
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.
2002,
Pubmed